​

Moleculin Biotech (MBRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MBRX Stock Rating

Moleculin Biotech stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

MBRX Price Target Upside V Benchmarks

TypeNameUpside
StockMoleculin Biotech-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.67$0.67$0.67
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 252----2
May, 252-1--3
Apr, 252-1--3
Mar, 252-1--3
Feb, 252----2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-15.07$-6.32----
Avg Forecast$-13.16$-7.57$-3.99$-3.88$-2.29$-2.06
High Forecast$-13.01$-7.57$-3.99$-3.10$-1.60$-2.06
Low Forecast$-13.16$-7.57$-3.99$-4.66$-2.98$-2.06
Surprise %14.51%-16.51%----

Revenue Forecast

$30M $42M $54M $66M $78M $90M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$34.43M$71.42M$41.96M$87.01M
High Forecast--$34.43M$71.42M$41.96M$87.01M
Low Forecast--$34.43M$71.42M$41.96M$87.01M
Surprise %------

Net Income Forecast

$-30M $-24M $-18M $-12M $-6M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-29.77M$-21.76M----
Avg Forecast$-25.85M$-14.95M$-7.88M$-7.67M$-4.52M$-4.07M
High Forecast$-25.71M$-14.95M$-7.88M$-6.12M$-3.16M$-4.07M
Low Forecast$-26.00M$-14.95M$-7.88M$-9.21M$-5.89M$-4.07M
Surprise %15.14%45.62%----

MBRX Forecast FAQ

Is Moleculin Biotech stock a buy?

Moleculin Biotech stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Moleculin Biotech is a favorable investment for most analysts.

What is Moleculin Biotech's price target?

Moleculin Biotech's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.67.

How does Moleculin Biotech stock forecast compare to its benchmarks?

Moleculin Biotech's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Moleculin Biotech over the past three months?

  • June 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 66.67% Strong Buy, 0% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 66.67% Strong Buy, 0% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Moleculin Biotech’s EPS forecast?

Moleculin Biotech's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.99, marking a -36.87% decrease from the reported $-6.32 in 2024. Estimates for the following years are $-3.88 in 2026, $-2.29 in 2027, and $-2.06 in 2028.

What is Moleculin Biotech’s revenue forecast?

Moleculin Biotech's average annual revenue forecast for its fiscal year ending in December 2025 is $34.43M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $71.42M, followed by $41.96M for 2027, and $87.01M for 2028.

What is Moleculin Biotech’s net income forecast?

Moleculin Biotech's net income forecast for the fiscal year ending in December 2025 stands at $-7.883M, representing a -63.78% decrease from the reported $-21.763M in 2024. Projections indicate $-7.665M in 2026, $-4.524M in 2027, and $-4.07M in 2028.